New Delhi | Jagran Lifestyle Desk: Swedish Biotechnology-major Enzymatica announced on Monday the results of its laboratory study for its mouth spray ColdZyme, to ‘deactivate’ SARS-CoV-2, the COVID-19 causing virus. The Biotechnology major said that its mouth spray ColdZyme deactivates the SARS-CoV-2 coronavirus by 98.3 per cent. 

The company, in its regulatory filing on Monday for ColdZyme, a mouth spray composed of glycerol and Atlantic cod trypsin, stated that its mouth spray offers a ‘protective barrier’ against SARS-CoV-2, and induces ‘local virus deactivation’ in the Oral cavity.

ColdZyme’s efficacy study, titled, “Standard Test Method to Assess the Activity of Microbicides against Viruses in Suspension”, was conducted by the US-based Microbac Laboratories Inc, which the regulatory filing said, found no cytotoxicity at any dilution level. Cytotoxicity refers to the ability of some agent to act toxically against the body’s cells.

An earlier in vitro study of Enzymatica had shown ColdZyme to be effective against another Coronavirus HCoV-229E, one of the causal-virus of common cold. The company did some changes in its formulation and on Monday it was proven to be effective against SARS-COV-2, the COVID-19 causing virus as well.

"Even if the current in vitro results cannot be directly translated into clinical efficacy, it is very interesting that ColdZyme can effectively deactivate SARS-CoV-2 in vitro since it constitutes a proof-of-principle that can be taken further into clinical studies. Thus, the results indicate that ColdZyme can offer a protective barrier against SARS-CoV-2," Claus Egstrand, Enzymatica's Chief Operating Officer was quoted as saying by PRS Newswire.

The COVID-19 causing virus increases its number by first infecting the cells in the throat and oral cavity, at the time of its mild-symptom causing state. ColdZyme once sprayed in mouth and throat could decrease the rate of spread of infection contagiously, and also decrease virus load locally.

Posted By: Aalok Sensharma